# A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)

> **NCT04166773** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 190 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Tirzepatide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04166773
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-19
- **Primary completion:** 2023-12-11
- **Final completion:** 2024-01-10
- **Target enrollment:** 190 (ACTUAL)
- **Last updated:** 2025-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04166773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04166773, "A Study of Tirzepatide (LY3298176) in Participants With Nonalcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT04166773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*